Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Receivables: 2010-2025

Historic Change in Receivables for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to -$1.3 million.

  • OptimizeRx's Change in Receivables fell 17119.11% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.5 million, marking a year-over-year increase of 2901.41%. This contributed to the annual value of $2.2 million for FY2024, which is 7511.76% down from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's Change in Receivables is -$1.3 million, which was down 17119.11% from $792000.0 recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Change in Receivables peaked at $12.0 million during Q4 2024, and registered a low of -$6.4 million during Q1 2024.
  • In the last 5 years, OptimizeRx's Change in Receivables had a median value of $227000.0 in 2023 and averaged $505742.5.
  • As far as peak fluctuations go, OptimizeRx's Change in Receivables soared by 41599.49% in 2023, and later plummeted by 240264.32% in 2024.
  • Over the past 5 years, OptimizeRx's Change in Receivables (Quarter) stood at $4.1 million in 2021, then rose by 12.26% to $4.6 million in 2022, then surged by 108.88% to $9.6 million in 2023, then grew by 25.25% to $12.0 million in 2024, then crashed by 110.74% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, $792000.0 for Q2 2025, and -$5.5 million during Q1 2025.